BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26455289)

  • 41. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
    Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases.
    Lee JJ; Cheng SJ; Wang YP; Jeng JH; Chiang CP; Kok SH
    Head Neck; 2013 Jan; 35(1):E6-10. PubMed ID: 21523843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents.
    Nicolatou-Galitis O; Papadopoulou E; Vardas E; Kouri M; Galiti D; Galitis E; Alexiou KE; Tsiklakis K; Ardavanis A; Razis E; Athanasiadis I; Droufakou S; Psyrri A; Karamouzis MV; Linardou H; Daliani D; Tzanninis D; Sachanas S; Laschos K; Kyrtsonis MC; Antoniou F; Laskarakis A; Giassas S; Nikolaidi A; Rigakos G; Ntokou A; Migliorati CA; Ripamonti CI
    Oral Dis; 2020 Jul; 26(5):955-966. PubMed ID: 32011077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ; Ramalingam L; Zacharin MR
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases.
    Junquera L; Gallego L; Cuesta P; Pelaz A; de Vicente JC
    Am J Otolaryngol; 2009; 30(6):390-5. PubMed ID: 19880027
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Osteonecrosis of the jaw developing during bisphosphonate treatment].
    Udvardy E; Redl P; Márton I
    Magy Onkol; 2008 Mar; 52(1):81-7. PubMed ID: 18403302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?
    Otto S; Tröltzsch M; Jambrovic V; Panya S; Probst F; Ristow O; Ehrenfeld M; Pautke C
    J Craniomaxillofac Surg; 2015 Jul; 43(6):847-54. PubMed ID: 25958767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
    Lobato JV; Maurício AC; Rodrigues JM; Cavaleiro MV; Cortez PP; Xavier L; Botelho C; Hussain NS; Santos JD
    J Plast Reconstr Aesthet Surg; 2008; 61(1):99-106. PubMed ID: 18068658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of BP-ONJ in osteopenic and healthy sheep: comparing ZTE-MRI with µCT.
    Voss P; Ludwig U; Poxleitner P; Bergmaier V; El-Shafi N; von Elverfeldt D; Stadelmann V; Hövener JB; Flügge T
    Dentomaxillofac Radiol; 2016; 45(4):20150250. PubMed ID: 26846710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E; Bamias A
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
    Migliorati CA; Siegel MA; Elting LS
    Lancet Oncol; 2006 Jun; 7(6):508-14. PubMed ID: 16750501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment.
    Ficarra G; Beninati F; Rubino I; Vannucchi A; Longo G; Tonelli P; Pini Prato G
    J Clin Periodontol; 2005 Nov; 32(11):1123-8. PubMed ID: 16212571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Bisphosphonates and osteonecrosis of the jaws].
    Urade M
    Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bisphosphonates: case report of nonsurgical periodontal therapy and osteochemonecrosis.
    Braun E; Iacono VJ
    Int J Periodontics Restorative Dent; 2006 Aug; 26(4):315-9. PubMed ID: 16939012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
    Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
    Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?
    Mawardi H; Treister N; Richardson P; Anderson K; Munshi N; Faiella RA; Woo SB
    J Oral Maxillofac Surg; 2009 Mar; 67(3):593-601. PubMed ID: 19231786
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.
    de Molon RS; Cheong S; Bezouglaia O; Dry SM; Pirih F; Cirelli JA; Aghaloo TL; Tetradis S
    Bone; 2014 Nov; 68():11-9. PubMed ID: 25093262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.